angiogenesis-related molecules ͉ tumor progression
C
ancer development and acquisition of malignant potential are multifactor and multistep processes that occur in a temporal manner during tumor progression (1, 2) . Significant components of these processes in the evolving neoplastic cell include development of growth signal autonomy, insensitivity to growth-inhibitory signals, evasion from apoptosis, unlimited replicative potential, and aberrant angiogenesis, as well as tissue invasion that can ultimately culminate in tumor dissemination (1) (2) (3) . An important defining element in controlling growth in both primary and metastatic tumors is new blood vessel formation (angiogenesis). The importance of angiogenesis in the growth of solid tumors is well established (3, 4) . Indeed, tumor size is restricted to a few cubic millimeters if it is not able to attract new blood vessels. Increased intratumoral microvascular density relative to normal tissue is observed in tumors of different tissues including the brain, colon, and breast (5) (6) (7) . Production of new vessels by the developing tumor and distant metastases results from the amplification of large quantities of pro-angiogenic molecules by both the tumor and host cells and reflects a net balance between positive and negative regulators of angiogenesis (8) (9) (10) . These observations emphasize that any genetic modification(s) in a cancer cell that culminates in expansion of tumor growth and metastasis will be inexorably linked to angiogenesis.
Astrocyte elevated gene (AEG)-1 was cloned by rapid subtraction hybridization as a gene induced in primary human fetal astrocytes (PHFA) infected with HIV-1 or treated with tumor necrosis factor-␣ (TNF-␣) (11) . Intriguingly, expression analysis revealed that AEG-1 was significantly elevated in subsets of breast carcinoma, melanoma, and malignant glioma cell lines compared to their normal cellular counterparts (12) . Its expression was also elevated in adult astrocytes transformed by SV40-T antigen, human telomerase reverse transcriptase (hTERT), and oncogenic Ha-ras that displayed an aggressive glioma-like phenotype (12) . AEG-1 synergized with oncogenic Ha-ras to enhance soft agar colony formation of SV40-T antigen-induced immortalized human melanocytes (FM516-SV) as well as in PHFA. Interestingly, AEG-1 itself is a downstream target of Ha-ras and plays an important role in mediating the growth-promoting effects of Ha-ras (13) . Overexpression of AEG-1 also augmented the anchorage-independent growth of HeLa cells and human glioma cell lines and increased their migration and invasion properties (14, 15) . Conversely, inhibition of AEG-1 by siRNA significantly inhibited migration and invasion of malignant glioma cells and prostate cancer cells and in vivo lung metastasis of breast cancer cells (16) (17) (18) (19) . In PHFA, FM516-SV, and cloned rat embryo fibroblasts (CREF), AEG-1 protects from serum starvation-induced apoptosis by activating the PI3K/Akt signaling pathway indicating, but not definitively proving, that AEG-1 might function as an oncogene (20) . Inhibition of AEG-1 in prostate cancer cells downregulated Akt activation and lead to upregulation of forkhead box (FOXO) 3a activity resulting in apoptosis (17) . Other studies identified AEG-1 homologs in rat and mouse, named Lyric/3D3 and Metadherin, respectively (18, 21, 22) , and provided evidence for its involvement in cancer progression and metastasis. In total, these observations indicate that AEG-1 may represent an essential gene regulating multiple signaling and biochemical pathways leading to cell transformation and tumor progression in diverse target cells.
A number of questions remain concerning the potential role(s) of AEG-1 in regulating the cancerous state and precisely what phenotypes it impacts on. These include foremost the biological consequences of elevated AEG-1 expression in normal cells in vitro and in vivo and its potential definitive role, if any, in angiogenesis, which as indicated above is a hallmark of cancer progression and metastasis. In this study, we demonstrate that AEG-1 can function as an oncogene, which when expressed at physiological levels in normal immortal CREF cells results in morphological transformation, enhanced invasion, anchorageindependent growth in agar, and acquisition of tumorigenic potential when injected into athymic nude mice. Additionally, sections of AEG-1-overexpressing tumors showed enhanced CD31 expression indicating that CREF-AEG-1 tumors are highly vascularized. In vitro angiogenesis assays with human umbilical vein endothelial cells (HUVECs) revealed that overexpression of AEG-1 significantly increased tube formation in Matrigel through PI3K/Akt signaling. Furthermore, overexpression of AEG-1 in HUVECs and malignant glioma cells modulated angiogenic regulators including Tie2 and hypoxia inducible factor 1 (HIF1)-␣. In total, the present studies now confirm that AEG-1 is indeed an oncogene and also a direct regulator of angiogenesis by upregulating key components in the process of blood vessel formation.
Results

AEG-1 Induces Invasion and Anchorage-Independent Growth in Nor-
mal Immortal CREF Cells. Anchorage-independent growth and invasion are two crucial events in tumor initiation and progression. Aberrant expression of AEG-1 modulates these phenotypes in HeLa, malignant glioma, prostate cancer, neuroblastoma, and hepatocellular carcinoma cells (14, 15, 17, 23, 24) . AEG-1 also synergizes with Ha-ras to augment the transformed phenotype in FM-516-SV and PHFA cells (12) . However, the oncogenic potential of AEG-1 as a single gene in nontransformed cells remained to be determined. To explore this possibility, CREF cells were engineered to stably express AEG-1 (Fig. 1) . We used CREF cells for this study because they can be morphologically transformed by single oncogenes, including Ha-ras, Ad E1A, v-Src, human papilloma virus type 18, and v-Raf, or high molecular weight human tumor-derived DNA (25, 26) , and can therefore serve as a sensitive barometer for monitoring oncogene functions (25) (26) (27) . As shown in Fig. 1 , parental CREF do not form macroscopic colonies in soft agar (Fig. 1B) and are minimally invasive ( Fig. 1 C and D) , whereas AEG-1-transformed clones all grow with variable efficiencies in soft agar and are highly invasive. Expression levels of AEG-1 positively correlated with agar cloning efficiency and invasive abilities of CREF-AEG-1 stable clones, suggesting a central role of AEG-1 in development of the transformed state. A concern when examining the function of transfected genes in cells is their level of expression and how this relates to true endogenous gene expression in untransfected cells. A comparison of the level of AEG-1 protein expressed endogenously in a series of human cancers and normal human cells indicated that the level of expression of AEG-1 in stable CREF-AEG-1 clone 2 and clone 30 is comparable or lower than observed in normal immortal human astrocyte, prostate, and melanocyte cells (Fig. 1 A) . In contrast, AEG-1 expression is significantly lower in these transformed CREF clones than in human cancers, including malignant gliomas, prostate cancers, and melanomas. These findings further support genuine oncogenic functions attributed to expression of human AEG-1 at physiologically relevant levels in CREF cells.
AEG-1 as a Single Gene Promotes Tumor Formation When Expressed
in CREF Cells. To evaluate oncogenic potential of cells expressing AEG-1 in vivo, nude mice were s.c. injected with CREF-AEG-1 clones (Fig. 2) . Inoculation of nude mice with CREF-AEG-1 cells (five independent clones of CREF genetically engineered to express elevated levels of AEG-1) resulted in the formation of aggressive and highly vascularized tumors (Figs. 2 and 3A) . In contrast, as previously observed (26, 28) , injection of nude mice with parental CREF cells did not generate any visible tumors. These in vivo results document that AEG-1 can function as an oncogene when expressed as a single genetic element at physiologically pertinent levels in immortal normal rat embryo cells resulting in an aggressive tumorigenic phenotype in nude mice.
AEG-1 Expression Directly Correlates with Increased Expression of
Angiogenesis Markers and Elevated Angiogenesis. On the basis of the morphology (high vascularization) of tumors in nude mice induced by CREF-AEG-1 cells (Fig. 3A) , we focused on angio- were seeded onto the upper chamber of a Matrigel invasion chamber system in the absence of serum. Twenty-four hours after seeding, the filters were fixed, stained, and photographed. (D) Quantitation of the invasion assay. The data expressed in the graph is the mean Ϯ SE of three independent experiments. * , P Ͻ 0.05 vs. CREF. (Fig. 3B ). AEG-1 staining was most prominent in the peri-nuclear region of the cells, with only a minority of tumor cells also showing nuclear staining (Fig. 3C) . Additional immunohistochemical analysis revealed that enhanced expression of AEG-1 in tumor sections augmented expression of specific angiogenesis molecules including angiopoietin-1 (Ang1), matrix metalloprotease (MMP)-2, and HIF1-␣ (Fig. 3C ), further supporting a potential role of AEG-1 in tumor angiogenesis.
AEG-1 Functions as a Potent Inducer of Angiogenesis.
Histochemical analysis of the CREF-AEG-1 tumors indicated potential angiogenic activities of AEG-1, which we investigated using in vitro angiogenesis assays. Tube formation is an important parameter of endothelial function in angiogenesis that can readily be evaluated and quantified in vitro. HUVECs cultured on Matrigel rapidly align, extend processes into the matrix, and finally form capillary-like structures surrounding a central lumen. Within 16 h after seeding on Matrigel, HUVECs start to form tubular structures (Fig. 4A ). Forced expression of AEG-1 by a replication incompetent adenovirus (Ad.AEG-1) significantly enhanced tube formation, with an increased number of intracellular contacts and overall complexity of the network (Fig. 4A) . Conversely, treatment of HUVECs with AEG-1 siRNA significantly inhibited VEGF-induced tube formation in Matrigel (Fig.  4B) . Next we used a chicken chorioallantoic membrane (CAM) angiogenesis model to study whether siRNA knockdown of AEG-1 would be a feasible approach to suppress tumor-induced angiogenesis in vivo. H4 glioma cells, previously shown to express elevated levels of AEG-1, were treated with either control or AEG-1 siRNA and seeded on fresh, 9-day-old CAMs. One week after seeding the cells, the CAMs were harvested. CAMs seeded with control siRNA-treated H4 cells caused outgrowth capillary neovascularization near the tumor core region (Fig. 4C, left) . On the other hand, CAMs seeded with AEG-1 si-RNA-treated H4 glioma cells exhibited little neovascularization (Fig. 4C, right) .
Previous studies have linked many AEG-1-induced cellular changes with PI3K/Akt signaling (13, 20) . PI3K/Akt regulates a number of processes associated with cancer progression including angiogenesis (29) . To analyze the potential importance of PI3K/Akt signaling in AEG-1-mediated angiogenesis, we used a recombinant replication-incompetent adenovirus expressing a dominant-negative Akt (Ad.DN.Akt). AEG-1-mediated endothelial cell tube formation was significantly inhibited by Ad.DN.Akt (Fig. 4A) , suggesting that the PI3K/Akt pathway is an integral component of this process.
Since endothelial cell migration and invasion are important steps in angiogenesis, we tested the effect of forced expression of AEG-1 on the invasive ability of HUVECs. As shown in Fig.  4D , overexpression of AEG-1 significantly enhanced the invasive ability of HUVECs, which was conversely blocked by inhibition of the PI3K/Akt pathway. Taken together, these results suggest that AEG-1 is a potent inducer of angiogenesis, and PI3K/Akt signaling is a necessary event in AEG-1-induced angiogenesis.
AEG-1 Modulates Angiogenic Regulators.
To further explore the mechanism(s) that mediate the pro-angiogenic activities of AEG-1, we investigated the effects of AEG-1 on Tie2 and HIF1-␣ expressions, which are commonly associated with angiogenesis. As shown in Fig. 5A , overexpression of AEG-1 significantly augmented the expressions of Tie2 and HIF1-␣ in HUVECs. Additionally, overexpression of AEG-1 significantly augmented the expression of HIF1-␣ in U87 and H4 human malignant glioma cells. This modulation of angiogenic regulators by AEG-1 was abrogated by co-expression of a dominant negative Akt, further supporting the involvement of PI3K/Akt signaling in AEG-1-induced angiogenesis. To test the specific role of Tie2 in the angiogenic activities of AEG-1, HUVECs were transfected with either control or Tie2 siRNA and infected with Ad.AEG-1 or an Ad vector not containing the AEG-1 gene (Ad.vec) as a control. Treatment with Tie2 siRNA significantly abrogated AEG-1-induced tube formation in Matrigel (Fig. 5B) , indicating that Tie2 plays a significant role in AEG-1-induced angiogenesis. Since vascular endothelial growth factor (VEGF) is a known inducer of angiogenesis and the Tie2 and VEGF receptor (VEGFR) pathways seem to work in a complementary and coordinated fashion during vascular development, we examined the effects of AEG-1 overexpression on VEGF promoter activity. As shown in Fig. 5 C and D, aberrant expression of AEG-1 in H4 cells modestly enhanced VEGF promoter activity, which was ablated by co-expression of a dominant-negative Akt or Tie2 siRNA, indicating the role of the PI3K/Akt pathway and Tie2 in the AEG-1-mediated VEGF induction.
Discussion
Cancer is a continuous process culminating in transformed cells that develop both qualitatively and quantitatively distinct properties as a tumor grows and evolves (30, 31 ). An initial step in conversion of a cell from normal to transformed can frequently involve the activation of a positive acting oncogene that significantly alters cellular phenotype (30, 31) . Additionally, it is now considered almost axiomatic that tumor progression is manifested by the ability of the cancer cell to grow in an unrestrained manner and establish secondary colonies, both of which require a well-developed set of blood vessels, i.e., angiogenesis, to sustain the growth of the primary and secondary metastatic tumors (32, 33) . In the last few years, multiple lines of evidence have suggested that AEG-1, a unique and highly conserved protein, plays a significant role in the progression of multiple cancers and metastasis. In the present study, we provide definitive evidence that AEG-1 can function directly as an oncogene and is also a potent inducer of angiogenesis.
Previous studies have demonstrated that AEG-1 can protect PHFA, rat embryo fibroblasts, and SV40-immortalized human melanocytes from serum-starvation-induced apoptosis (20) . AEG-1 alone modestly increases soft agar growth of PHFA, but can synergize with Ha-ras to significantly augment anchorageindependent growth (12) . In addition, we now demonstrate that AEG-1 as a single genetic element can significantly augment anchorage-independent growth in normal immortal CREF cells (Fig. 1B) and can induce aggressive tumor growth in nude mice (Fig. 2) . Tumors developing from injection with CREF-AEG-1 clones are highly vascularized and express elevated levels of CD31 (Fig. 3B) , a marker of angiogenesis. CREF-AEG-1 tumors also display high levels of additional angiogenic markers, including Ang1, MMP-2, and HIF1-␣ (Fig. 3C) . Moreover, we have recently shown that overexpression of AEG-1 in nontumorigenic human hepatocellular carcinoma cells also results in highly aggressive and vascularized tumors (24) . These findings provide support for the hypothesis that AEG-1 might be a positive regulator of angiogenesis. This is indeed the case, since we now show that overexpression of AEG-1 in HUVECs significantly enhances tube formation in Matrigel (Fig. 4A) ; conversely, knockdown of AEG-1 using siRNA significantly abrogates VEGF-induced tube formation in Matrigel (Fig. 4B) .
To elucidate the precise molecular mechanism underlying AEG-1 function as an angiogenesis inducer, we focused on expression of Tie2, HIF1-␣, and Ang1 in AEG-1-overexpressing HUVECs, U87, and H4 malignant glioma cells. Ang1 and Ang2 function as ligands for Tie2, a tyrosine kinase receptor predominantly expressed in vascular endothelial cells. Ang1 specifically induces tyrosine phosphorylation of Tie2, which results in the activation of multiple activities related to angiogenesis such as endothelial cell migration, tube formation, sprouting, and survival (34, 35) . Upregulation of Ang1 in high-grade gliomas, non-small cell lung carcinomas, and ovarian, breast, and gastric carcinomas strongly correlate with tumor malignancy (36) (37) (38) (39) (40) . Furthermore, overexpression of Ang1 in HeLa, GS9L, and in some established glioma cell lines has been reported to increase tumor growth (41) (42) (43) . Increased Tie2 levels were found in the vasculature of a number of human tumors, including breast cancer, non-small cell lung cancer, hepatocellular carcinoma, prostate cancer, hemangioma, and astrocytoma, and these levels were found to correlate with increasing malignancy (37, (44) (45) (46) (47) . Recent studies indicate that Tie2 plays a significant role in angiogenesis occurring in cancer (44) (45) (46) (47) . Suppression of Tie2 signaling (47-49) using specific inhibitors, such as soluble dominant-negative receptors, an antisense oligonucleotide, RNA aptamers, RNA interference, or a short synthetic peptide, promotes antitumor effects by restraining tumor angiogenesis. In these contexts, modulation of Tie2 and Ang1 by AEG-1 (Fig. 5A ) provides a mechanistic model by which AEG-1 regulates tumor angiogenesis (Fig. 6) . We also show that AEG-1 enhances HIF-1␣ expression in HUVECs, U87, and H4 human malignant glioma cells (Fig. 5A) . HIF-1 is expressed in hypoxic tumor cells Fig. 4 . Forty-eight hours after infection, total cellular extracts were prepared in RIPA buffer. Equal amounts of proteins were separated on 8 -12% SDS-PAGE, transferred onto nitrocellulose membrane and probed with a chicken polyclonal AEG-1, a rabbit polyclonal Tie2 and Ang1, and a mouse monoclonal HIF1-␣ antibodies. EF1␣ was used as a control to confirm equal protein loading. (B) HUVECs were transfected with either control siRNA or Tie2 siRNA and then infected with Ad.vec or Ad.AEG-1 (25 PFU/cell). One day after infection, cells (5 ϫ 10 4 ) were seeded onto Matrigel, and tube formation was assayed after 16 h. The data expressed in the graph is the mean Ϯ SE of three independent experiments. and transactivates various hypoxia-responsive genes, which confer malignant properties to tumors including apoptosisresistance and enhanced tumor growth, invasion, and metastasis (50) . In addition, HIF-1 activates pro-angiogenic cytokines such as VEGF and platelet-derived growth factor, which increase the proliferation and re-growth of tumor blood vessels (50, 51) . We now show that AEG-1 also activates the VEGF promoter in malignant glioma cells (Fig. 5C ), which is in agreement with observations from our group in stable hepatocellular carcinoma cells overexpressing AEG-1 that display elevated levels of VEGF, placental growth factor (PIGF) and fibroblast growth factor ␣ (FGF␣) compared to parental hepatocellular carcinoma cells (24) . Our results also reveal the central contribution of PI3K/Akt signaling in AEG-1-induced angiogenesis. Ang1 regulates endothelial cell survival through the PI3K/Akt pathway (52) . Overexpression of a dominant-negative Akt construct inhibits Ang1-mediated endothelial cell survival (53) , supporting a critical role of Akt in Tie2/Ang-mediated endothelial cell survival. Additionally, both Ang1-and VEGF-induced endothelial cell survival are partially regulated through the PI3K/Akt pathway. In these contexts, our results firmly establish PI3K/Akt signaling as one of the primary mediators of AEG-1-induced angiogenesis in both normal HUVECs and malignant glioma cells. The Ras/MEK signaling pathway is another major pathway for regulating angiogenesis. Thus, our observation of an approximately 50% reduction in tube formation by inhibition of the PI3K/Akt pathway in AEG-1 overexpressing HUVECs (Fig. 4) indicates that other signaling pathways might partially contribute to AEG-1-induced increased angiogenesis. Future studies are required to clarify the complex mechanisms involved in this phenomenon.
In conclusion, this study evaluates the direct oncogenic potential of AEG-1 as a single gene in nontransformed normal cells. Our data show that AEG-1 plays a crucial role in both oncogenic transformation and angiogenesis, which are essential components in tumor cell development, growth, and progression to metastasis (54) . In the contexts of angiogenesis, we define important changes induced by AEG-1 in both HUVECs and malignant glioma cells, namely upregulation of Ang1 and Tie2, as potential factors underlying pro-angiogenic activity of AEG-1. We further document the importance of PI3K/Akt signaling in mediating pro-angiogenic action of AEG-1. The present studies provide mechanistic insights into AEG-1 function and support the development of therapeutic strategies that target this gene (or its downstream mediators of transformation and angiogenesis) by a genetic (antisense or siRNA) or pharmacological (small-molecule) inhibitor approach to develop an effective rational target-based strategy for the therapy of multiple cancers (54) .
Materials and Methods
Cell Lines and Culture Conditions. CREF is a specific clone of Fischer F2408 rat embryo fibroblast cells (55) . CREF-AEG-1 clone 2, 3, 25, 29, and 30 are hygromycin-resistant stable clones obtained after transfection of CREF cells with pcDNA3.1-AEG-1 and selected for growth in 100 g/mL hygromycin (Invitrogen). Normal human cells, PHFA, P69 (SV40-immortalized normal human prostate epithelial cells), and FM516-SV, have been described in ref. 20 . Human tumor cells, U87MG and H4 (malignant glioma); DU-145 and PC-3 (prostate carcinoma); and HO-1 and C8161 (metastatic melanoma cells), have been described (12, 15) . Cells resistant to hygromycin were maintained in medium containing 50 g/mL hygromycin. HUVEC cells were purchased from Cambrex and maintained according to manufacturer's instructions.
Xenograft Studies in Athymic Nude
Mice. Xenograft studies in nude mice with CREF, CREF-AEG-1 clone 2, 3, 25, 29, and 30 (CREF stably transfected with the human AEG-1 cDNA) were performed as described (23, 24) . Four weeks after injection, mice were killed, tumors were weighed and measured, and tumors were fixed in 10% neutral buffered formalin for the immunohistochemical studies. Statistical significance between the groups was determined by unpaired two-tailed Student's t test. A P value of Ͻ 0.05 was considered significant.
Immunohistochemistry. Formalin-fixed tumors were embedded in paraffin, sectioned, and mounted on glass slides (55) . Immunohistochemical staining was performed with anti-rabbit AEG-1, Ang1, and MMP-2, and anti-mouse CD31 and HIF1-␣ antibodies as described in ref. 24 .
Recombinant Adenovirus Constructs and siRNAs. The recombinant replicationincompetent Ad.AEG-1 and Ad.DN.Akt and the control and AEG-1 siRNAs were described (13, 20) . Tie2 siRNA was purchased from Santa Cruz Biotechnology. The transfection of siRNA was performed as described in ref. 13 .
Invasion Assays. Invasion assays were performed by using 24-well BioCoat cell culture inserts with an 8--porosity polyethylene terepthylate membrane coated with Matrigel basement membrane matrix (100 g/cm 2 ) as described in ref. 15 . The invasive ability of the cells was determined by counting of the cells that had migrated to the lower side of the filter with a microscope (magnification, ϫ100). Experiments were assayed in triplicate, and at least 10 fields were counted in each experiment.
Anchorage-Independent Growth Assay in Soft Agar. Anchorage-independent growth assays were performed by seeding 1 ϫ 10 5 cells in 0.4% Noble agar on an 0.8% agar base layer, both of which contained growth medium. Colonies were counted (Ͼ0.1-mm) 2 weeks after seeding, and the data from triplicate determinations were expressed as mean Ϯ SD.
Western Blot Analysis. Whole-cell lysates were prepared, and Western blot analysis was done as described in ref. 14. The primary antibodies used were anti-AEG-1 (chicken polyclonal, 1:2,000), anti-HIF1-␣ (mouse monoclonal, 1:500; AbCam), anti-EF1␣ (mouse monoclonal, 1:1,000; Upstate Biotechnology), anti-Tie2, and anti-Ang1 (rabbit polyclonal, 1:500; Santa Cruz Biotechnology).
Capillary-Like Tube Formation Assay. The formation of tube-like structures by HUVECs on Matrigel (Chemicon) was performed as described in ref. 56 . The adenovirus-transduced or siRNA-transfected HUVECs (pretreated with calcein-AM) were seeded on coated plates at 5 ϫ 10 4 cells/well in EGM containing 2% FBS and incubated at 37°C for overnight. Cells were observed using a Fluorescence microscope (Nikon). Images were captured with a video graphic system. The degree of network formation was quantified using Image analyzer (National Institutes of Health Image). 
